ATTORNEY'S DOCKET NUMBER U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FISHMAN19A TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) 10/565161 **CONCERNING A FILING UNDER 35 U.S.C. 371** INTERNATIONAL FILING DATE PRIORITY CLAIMED INTERNATIONAL APPLICATION NO. November 30, 2005 December 2, 2004 PCT/IL2005/001280 TITLE OF INVENTION TREATMENT OF INFLAMMATION APPLICANT(S) FOR DO/EO/US Pnina FISHMAN et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. [X] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371. 2. [ ] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. [X] This is an express request to begin national examination procedures (35 U.S.C. 371(f)) as soon as the application is in order for such purpose and the applicable requirements of 35 U.S.C. 371(c) have been complied with. 4. [ ] The US has been elected (Art 31). 5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. [ ] is attached hereto (required only if not transmitted by the International Bureau). b. [X] has been communicated by the International Bureau. c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US). 6. [ ] An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. [ ] is attached hereto. b. [ ] has been previously submitted under 35 U.S.C. 154(d)(4). 7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. [ ] are transmitted herewith (required only if not transmitted by the International Bureau). b. [ ] have been communicated by the International Bureau. c. [ ] have not been made; however, the time limit for making such amendments has NOT expired. d. [X] have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. [ ] An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included: 11. [ ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. [ ] An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. [X] A FIRST preliminary amendment. 14. [X] An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A change of power of attorney and/or address letter. 17. [ ] A computer-readable sequence form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. [ ] A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. [ ] A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4) 20. [X] Other items or information: [X] Courtesy copy of the International Application as filed. [X] Formal drawings, 2 sheets, Figures 1A-2B. [X] The application is (or will be) assigned to: CAN-FITE BIOPHARMA LTD. whose address is 10 Bareket Street, Petach Tikva 49170, Israel.

Page 1 of 2

U.S. APPLICATION N	Q. (If know	see 37 CER	1.5)	International Application No.			Attorney's Docke	
10/565161 PCT/IL2005/001280 21. The following fees are submitted:						FISHMAN19A  CALCULATIONS PTO USE ONLY		
21. The following ices are submitted.							CALCULATIONS PROUSE ONLY	
[xx] a) BASIC NATIONAL FEE (37 CFR 1.492(a))\$300.00								
[xx] b) SEARCH FEE (37 CFR 1.492(b))								
US was International Searching Authority\$100.00								
Other ISR provided to USPTO\$400.00								
[xx] All other situations							\$1,000.00	
[xx] c) EXAMINATION FEE (37 CFR 1.492 (c))							41,000.00	
IPEA/US gave wholly favorable IPER\$100.00								
1	[xx] All other situations\$200.00							
TOTAL OF ABOVE CALCULATIONS:								
Surcharge of \$130.00 for furnishing the oath or declaration later than [ ]20 [ ]30							\$	
months from the earliest claimed priority date (37 CFR 1.492(h)).								
TOTAL SHEETS	EXTRA					RATE (1.492(g))		•
29 - 100		/50	•			X \$250.00		
CLAIMS		Number		Number Extra	I	.492 (d-f))		
	Total Claims		20 =	1	X \$ 50.00 X \$200.00		\$50.00	
Independent Claims  Multiple Dependent Claims (		3 - 3 =			+ \$36		\$	
Wattpie Dependent	t Claims (II	аррисаотс)		TOTAL OF ABOVE			\$1,050.00	
Reduction of ½ for filing by small entity, if applicable. Applicant claims small entity status. See 37							\$525.00	
CFR 1.27.							\$525.00	
SUBTOTAL =  Processing fee of \$130.00 for furnishing the English translation later than [ ] 20 [ ] 30							\$323.00	
months from the earliest claimed priority date (37 CFR 1.492(i)).								
TOTAL NATIONAL FEE =						\$525.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +						\$		
TOTAL FEES ENCLOSED =						\$525.00		
							Amount to be: refunded	\$
							charged	\$
Payment Method (check one only)								<u> </u>
a. [ ] A check in the amount of \$ to cover the above fees is enclosed.								
a. [ ] A check in the amount of a to cover the above fees is enclosed.								
b. [X] Credit Card Payment Form (PTO-2038), authorizing payment in the amount of \$525.00, is attached.								
c. [ ] Please charge my Deposit Account No. 02-4035 in the amount of \$ to cover the above fees.								
A duplicate copy of this sheet is enclosed.								
Handling of Fig. Deficiencies (about a grants)								
Handling of Fee Deficiencies (check one only)								
[X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <b>02-4035</b> . A duplicate copy of this sheet is enclosed.								
[ ] If a deficiency exists in the basic national fee set by 37 CFR 1.492(a), please charge it to Deposit Account <b>02-4035</b> . At this time, no authorization is given to charge any other fees.								
NOTE: Whose an appropriate time limit and an 27 CED 1 404 or 1 405 by the limit and an 27 CED 1 404 by the limit and an 27 CED 1 404 by the limit and an 27 CED 1 404 by the limit and an 27 CED 1 404 by the limit and an 27 CED 1 404 by the limit and an 27 CED 1 404 by the limit and an 27 CED 1 404 by the limit and an 27 CED 1 404 by the limit and an 27 CED 1 404 by the limit and an 27 CED 1 404 by the limi								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a)) or (b)) must be filed and granted to restore the application to pending status.								
Direct all correspondence to the address associated with  CUSTOMER NUMBER 001444, which is currently:							A-11/-	kurar >
							SIGNATURE	
							Sheridan Neimark	<u> </u>
l control of the state of the s							NAME	
WASHINGTON, D.C. 20001 TEL: (202) 628-5197							20,520 REGISTRATION NUMBER	
FAX: (202) 737-						ŗ	COULTY HON NOWING	-11
Date of this submission: January 19, 2006							SN:lmh	